(Q35671356)

English

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

scientific article published on 6 April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105 (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

21

object named as

James M Ford

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

13

object named as

Joseph A Sparano

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Allison W. Kurian

4

object named as

Allison W Kurian

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

Melinda L Telli

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Kristin C Jensen

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Shaveta Vinayak

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Jafi A Lipson

5

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Patrick J Flaherty

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Kirsten Timms

7

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Victor Abkevich

8

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Elizabeth A Schackmann

9

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Irene L Wapnir

10

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Robert W Carlson

11

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Pei-Jen Chang

12

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Bobbie Head

14

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Lori J Goldstein

15

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Barbara Haley

16

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Shaker R Dakhil

17

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Julia E Reid

18

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Anne-Renee Hartman

19

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Judith Manola

20

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

6 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1895-1901

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Novel treatment approaches for triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Supervised risk predictor of breast cancer based on intrinsic subtypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

The role of BRCA1 in the cellular response to chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

12 July 2018

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4451172

25 September 2018

The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/25847929

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2014.57.0085

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35671356&oldid=2137032760"